Table 1 Clinical and biologic characteristics of patients stratified by lymphoid neogenesis
Demographic | All (n = 46) | LN+ (n = 20) | LN- (n = 26) | P |
|---|---|---|---|---|
Age (years) | 50 (37; 61) | 48 (36; 59) | 54 (38.5; 63) | NS |
Male (%) | 26 (57) | 13 (65) | 13 (50) | NS |
Disease duration (years) | 7.5 (3.75; 13) | 6 (2; 14) | 8 (4.5; 12.5) | NS |
Follow-up (months) | 27 (9; 52) | 21 (8; 50) | 27 (12; 55) | NS |
Clinical status | ||||
TJC | 1 (1; 2) | 1 (1; 2) | 1 (1; 2) | NS |
SJC | 1 (1; 2) | 1 (1; 2) | 1 (1; 2) | NS |
Articular pattern, n (%) | ||||
Oligoarthritis | 23 (50) | 13 (57) | 10 (43) | NS |
Poliarthritis | 18 (39) | 7 (39) | 11 (61) | |
Mixed (peripheral plus axial) | 5 (11) | 2 (40) | 3 (60) | |
ESR (mm/h) | 19 (10; 30) | 20 (9; 31) | 18 (12; 25) | NS |
CRP (mg/dl) | 0.72 (0.32; 2.01) | 1.00 (0.51; 1.83) | 0.44 (0.29; 2.32) | NS |
DAS28 | 3.31 (3.01; 4.2) | 3.31 (2.94; 4.14) | 3.34 (3.01; 4.28) | NS |
Erosive disease, n (%) | 12 (26) | 7 (35) | 5 (19) | NS |
Treatment | ||||
DMARDs taken, n (%) | 23 (50) | 12 (60) | 11 (42) | NS |
TNF-blockers, n (%) | 8 (17) | 1 (5) | 7 (27) | 0.041 |
EULAR response | Treated (n = 28) | LN+ (n = 11) | LN- (n = 17) | P |
No response, n (%) | 8 (29) | 3 (27) | 5 (29) | 0.541 |
Moderate, n (%) | 7 (25) | 4 (36) | 3 (18) | |
Good, n (%) | 13 (46) | 4 (36) | 9 (53) | |